Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Adipose-Derived Stem & Regenerative Cells Improve Fat Graft Retention in Preclinical Study

December 15, 2007

Cytori Therapeutics, Inc. (NASDAQ:CYTX) reported positive preclinical results demonstrating adipose-derived stem and regenerative cells improved the quality and long-term retention of a fat graft, representing a potential new approach in reconstructive surgery. The benefit of adipose-derived stem and regenerative cells was observed at six months and was retained through the end of the study at nine months. Results were presented at the 30th annual San Antonio Breast Cancer Symposium. (Poster #4072)

“Fat tissue transfers enhanced with adipose tissue-derived stem and regenerative cells can provide a novel option for reconstructive surgery,” said Marc H. Hedrick, M.D., president of Cytori Therapeutics. “Using Cytori’s Celution™ System to provide stem and regenerative cells would simplify, standardize and improve the predictability of shape and volume outcomes for fat transfer procedures, including breast reconstruction following partial mastectomy.”

In the preclinical rodent study, donor adipose-derived stem and regenerative cells, or saline, was combined with donor adipose tissue and then transplanted onto recipient skulls. After six and nine months, grafts were harvested and weighed. The mean weight of cell-enhanced grafts at six and nine months was two times greater than grafts with saline (p = 0.019 at six months; p=0.034 at nine months). Histological analysis revealed the cell-enhanced grafts contained less fibrous tissue, suggesting improved graft quality. Additionally, donor stem and regenerative cells were present within grafted adipose tissue and were incorporated into blood vessel walls within the fat graft.

A related preclinical study further established safety of adipose-derived stem and regenerative cells by demonstrating these cells had no effect on the promotion of tumor growth. Human fat grafts with or without adipose-derived stem and regenerative cells were transplanted onto mammary fad pads of rodent recipients injected with human breast cancer cells. The study was repeated with three human fat donors. After eight weeks, the study found no evidence that enhancing the fat graft of any of the donors with stem and regenerative cells had any effect on the in vivo growth rate, volume, or metastasis of the human breast tumors.

Cytori Therapeutics

Cytori Therapeutics’ (NASDAQ: CYTX) goal is to be the global leader in regenerative medicine. The company is dedicated to providing patients with new options for reconstructive surgery, developing treatments for cardiovascular disease, and banking patients’ adult stem and regenerative cells. To reach its goal, Cytori is developing its innovative Celution™ System to separate and concentrate a patient’s own adult stem and regenerative cells from adipose (fat) tissue for these cells to be delivered back to the patient during the same surgical procedure. The Celution™ System will be introduced in 2008 in Europe for reconstructive surgery and launched in Japan for cryopreserving a patient’s own stem and regenerative cells. Clinical trials are ongoing or planned in cardiovascular disease, spinal disc degeneration, gastrointestinal disorders, and other unmet medical needs. www.cytoritx.com

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements regarding events, trends and prospects of our business, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses, the need for further financing, regulatory uncertainties, dependence on performance of third parties, and other risks and uncertainties described (under the heading “Risk Factors”) in Cytori Therapeutics’ Form 10-K annual report for the year ended December 31, 2006. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.